Articles related to DEPRESSION

The FDA-designated Class II recall affects specific duloxetine lots where exposure may lead to “temporary or medically reversible health consequences or where the probability of serious adverse health consequences is remote.”

A new network meta-analysis reveals that high-dose psilocybin may be as effective as escitalopram for treating depressive symptoms, with a standardized mean difference of 0.31 compared to placebo in antidepressant trials.

Clinicians treating cancer and kidney disease patients prescribed antidepressants at rates similar to outpatient psychiatrists, highlighting the prevalence of depression management across specialties.

The FDA-approved Rejoyn app, designed for major depressive disorder, combines therapeutic exercises and emotional regulation training to complement antidepressant therapy, showing significant improvement in clinical trials.

Recent studies indicate that while ketamine and ECT are equally effective for treating MDD, ketamine did not prove non-inferior to ECT for MDEs. Both treatments have distinct side effect profiles that are critical for clinical decision-making.

Among the approved SGAs for MDD, no single medication stands out as the first choice; decision-making is guided by individual patient profiles and side effect considerations.